logo-loader

Q BioMed forms license agreement with Europe and Middle East distributor to sell Strontium89

Published: 09:21 14 Jul 2021 EDT

Q BioMed Inc (OTCQB:QBIO) Chief Commercial Officer Kristin Keller tells Proactive the New York-based group has struck an exclusive license agreement with authorized Europe and Middle East distributor Clionix for the distribution and sales of the company’s metastatic bone pain drug Strontium89.

Keller says Clionix has received “exclusive rights” to distribute Strontium89 in Turkey, Saudi Arabia, Azerbaijan, Bulgaria, Romania, Egypt, Kuwait and Pakistan.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 25 minutes ago